We are live on ! Find out more
BBA

Baker Bros. Advisors Portfolio holdings

AUM $17.4B
1-Year Est. Return 131.5%
This Fund
S&P 500
This Quarter Est. Return
+6.01%
1 Year Est. Return
+131.5%
3 Year Est. Return
+336.81%
5 Year Est. Return
+553.16%
10 Year Est. Return
+4,134.93%
AUM
$9.04B
AUM Growth
-$325M
Cap. Flow
-$209M
Cap. Flow %
-2.31%
Top 10 Hldgs %
81.82%
Holding
98
New
4
Increased
11
Reduced
16
Closed
9

Top Buys

Rank Stock Value
1
IMVT icon
Immunovant
IMVT
+$78.4M
2
PCVX icon
Vaxcyte
PCVX
+$47.3M
3
INSM icon
Insmed
INSM
+$28.6M
4
IMCR icon
Immunocore
IMCR
+$24.2M
5
CELC icon
Celcuity
CELC
+$17.9M

Top Sells

Rank Stock Value
1
ONC
BeOne Medicines Ltd
ONC
+$171M
2
CRSP icon
CRISPR Therapeutics
CRSP
+$27.7M
3
KRYS icon
Krystal Biotech
KRYS
+$26.6M
4
RYTM icon
Rhythm Pharmaceuticals
RYTM
+$26.6M
5
XENE icon
Xenon Pharmaceuticals
XENE
+$24.5M

Sector Composition

Rank Sector Weight
1 Healthcare 98.87%
2 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ONC
1
BeOne Medicines Ltd
ONC
$34.2B
$2.39B 26.5%
8,799,053
-732,827
-8% -$171M
INCY icon
2
Incyte
INCY
$25.5B
$1.86B 20.6%
30,739,953
+487
+0% +$34K
ACAD icon
3
Acadia Pharmaceuticals
ACAD
$4.52B
$712M 7.88%
42,877,916
– –
MDGL icon
4
Madrigal Pharmaceuticals
MDGL
$12.6B
$654M 7.24%
1,974,590
– –
SMMT icon
5
Summit Therapeutics
SMMT
$10.4B
$471M 5.21%
24,424,865
– –
INSM icon
6
Insmed
INSM
$22.6B
$410M 4.54%
5,380,626
+373,763
+7% +$28.6M
RYTM icon
7
Rhythm Pharmaceuticals
RYTM
$7.42B
$297M 3.29%
5,604,483
-479,766
-8% -$26.6M
RVMD icon
8
Revolution Medicines
RVMD
$39.1B
$281M 3.11%
7,936,972
– –
KYMR icon
9
Kymera Therapeutics
KYMR
$8.88B
$164M 1.82%
5,995,929
– –
ALKS icon
10
Alkermes
ALKS
$8.26B
$148M 1.64%
4,483,285
+301,534
+7% +$9.83M
EWTX icon
11
Edgewise Therapeutics
EWTX
$4.38B
$135M 1.5%
6,155,940
– –
REPL icon
12
Replimune Group
REPL
$463M
$108M 1.19%
11,045,336
– –
IMVT icon
13
Immunovant
IMVT
$8.03B
$93.3M 1.03%
5,457,881
+3,750,000
+220% +$78.4M
BCYC
14
Bicycle Therapeutics
BCYC
$274M
$92.4M 1.02%
10,885,357
– –
IMCR icon
15
Immunocore
IMCR
$1.71B
$68.9M 0.76%
2,322,656
+807,338
+53% +$24.2M
KNSA icon
16
Kiniksa Pharmaceuticals
KNSA
$6.23B
$62.6M 0.69%
2,818,323
– –
ABCL icon
17
AbCellera Biologics
ABCL
$1.69B
$61.4M 0.68%
27,525,640
– –
RARE icon
18
Ultragenyx Pharmaceutical
RARE
$2.5B
$57.1M 0.63%
1,576,114
– –
DNLI icon
19
Denali Therapeutics
DNLI
$3.86B
$50.7M 0.56%
3,731,695
– –
KOD icon
20
Kodiak Sciences
KOD
$2.59B
$48.6M 0.54%
17,310,490
– –
NRIX icon
21
Nurix Therapeutics
NRIX
$2.5B
$46.1M 0.51%
3,882,125
– –
ARGX icon
22
argenx
ARGX
$55.3B
$46M 0.51%
77,760
-34,144
-31% -$21.5M
TRDA icon
23
Entrada Therapeutics
TRDA
$260M
$44M 0.49%
4,865,819
– –
CELC icon
24
Celcuity
CELC
$4.09B
$43M 0.48%
4,257,735
+1,579,182
+59% +$17.9M
GRAL
25
GRAIL Inc
GRAL
$2.82B
$41.6M 0.46%
1,630,125
– –
1
2 3 4

Similar funds

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
VMPIC
Varma Mutual Pension Insurance Co Helsinki, Finland $17B AUM 24.09% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
BCIM
British Columbia Investment Management Victoria, British Columbia, Canada $17B AUM 31.69% 1-Year Est. Return

Baker Bros. Advisors's Q1 2025 Portfolio in Review

As of Q1 2025, Baker Bros. Advisors held 98 positions worth $9.04B, down 3.5% from $9.36B the previous quarter. Its ten largest holdings account for 82% of the portfolio.

Baker Bros. Advisors's Q1 2025 filing shows 4 new, 11 increased, 16 reduced and 9 closed positions. Its largest new stake was Verona Pharma: 223,843 shares worth $14.2M. The largest sale was BeOne Medicines Ltd, an estimated $171M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 99% a quarter earlier, followed by Financials.

  • Baker Bros. Advisors's largest Q1 2025 buy was Verona Pharma: 223,843 shares worth $14.2M.
  • Baker Bros. Advisors added most to Immunovant in Q1 2025, an estimated $78.4M increase.
  • Baker Bros. Advisors's biggest Q1 2025 reduction was BeOne Medicines Ltd, cutting an estimated $171M.
  • Baker Bros. Advisors fully exited Krystal Biotech in Q1 2025, selling an estimated $26.6M.
  • Baker Bros. Advisors's ten largest holdings make up 82% of its $9.04B portfolio in Q1 2025.
  • Baker Bros. Advisors opened 4 new positions and closed 9 in Q1 2025.
  • Baker Bros. Advisors's portfolio value fell 3.5% quarter-over-quarter to $9.04B.

Based on Baker Bros. Advisors's 13F filing for Q1 2025, filed 15 May 2025.